Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health-care products giant Johnson & Johnson (NYSE:JNJ) has earned a respected four-star ranking.

With that in mind, let's take a closer look at J&J and see what CAPS investors are saying about the stock right now.

J&J facts

Headquarters (founded)

New Brunswick, N.J. (1886)

Market Cap

$265.1 billion

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$70.0 billion

Management

Chairman/CEO Alex Gorsky
CFO Dominic Caruso

Return on Equity (average, past 3 years)

17.9%

Cash/Debt

$25.1 billion / $15.0 billion

Dividend Yield

2.8%

Competitors

Covidien
Novartis
Pfizer

Sources: S&P Capital IQ and Motley Fool CAPS.

Earlier this summer, CAPS member NHWeston102 succinctly summed up the J&J bull case for our community:

JnJ has taken its lumps of late, but it is still a global company with a huge spectrum of well-known brands from baby-powder to band-aids. They are not afraid to buy pioneering companies to catch a leg up on the competition, but JnJ still retains a strong innovative edge of its own. Look, for example, at INVOCANA, a diabetes drug that controls glucose levels through urine stream rather than insulin regulation. A classic buy-and-hold blue chip that still has serious class!!  


Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Covidien and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.